Your browser doesn't support javascript.
Understanding the Prevalence and Geographic Heterogeneity of SARS-CoV-2 Infection: Findings of the First Serosurvey in Uttar Pradesh, India.
Namasivayam, Vasanthakumar; Jain, Amita; Agrawal, Vikasendu; Prakash, Ravi; Dehury, Bidyadhar; Becker, Marissa; Blanchard, James; Isac, Shajy; Prasad, Amit Mohan.
  • Namasivayam V; Department of Community Health Sciences, Institute for Global Public Health, University of Manitoba, R070 Med Rehab Bldg, 771 McDermot Avenue, Winnipeg, MB, R3E 0T6, Canada. drvasanth@ihat.in.
  • Jain A; King George's Medical University (KGMU), Lucknow, India.
  • Agrawal V; Government of Uttar Pradesh, Lucknow, India.
  • Prakash R; Department of Community Health Sciences, Institute for Global Public Health, University of Manitoba, R070 Med Rehab Bldg, 771 McDermot Avenue, Winnipeg, MB, R3E 0T6, Canada.
  • Dehury B; India Health Action Trust, New Delhi/Lucknow, India.
  • Becker M; Department of Community Health Sciences, Institute for Global Public Health, University of Manitoba, R070 Med Rehab Bldg, 771 McDermot Avenue, Winnipeg, MB, R3E 0T6, Canada.
  • Blanchard J; Department of Community Health Sciences, Institute for Global Public Health, University of Manitoba, R070 Med Rehab Bldg, 771 McDermot Avenue, Winnipeg, MB, R3E 0T6, Canada.
  • Isac S; Department of Community Health Sciences, Institute for Global Public Health, University of Manitoba, R070 Med Rehab Bldg, 771 McDermot Avenue, Winnipeg, MB, R3E 0T6, Canada.
  • Prasad AM; India Health Action Trust, New Delhi/Lucknow, India.
J Epidemiol Glob Health ; 11(4): 364-376, 2021 12.
Article in English | MEDLINE | ID: covidwho-1491553
ABSTRACT
Population-based serological antibody test for SARS-CoV-2 infection helps in estimating the exposure in the community. We present the findings of the first district representative seroepidemiological survey conducted between 4 and 10 September 2020 among the population aged 5 years and above in the state of Uttar Pradesh, India. Multi-stage cluster sampling was used to select participants from 495 primary sampling units (villages in rural areas and wards in urban areas) across 11 selected districts to provide district-level seroprevalence disaggregated by place of residence (rural/urban), age (5-17 years/aged 18 +) and gender. A venous blood sample was collected to determine seroprevalence. Of 16,012 individuals enrolled in the study, 22.2% [95% CI 21.5-22.9] equating to about 10.4 million population in 11 districts were already exposed to SARS-CoV-2 infection by mid-September 2020. The overall seroprevalence was significantly higher in urban areas (30.6%, 95% CI 29.4-31.7) compared to rural areas (14.7%, 95% CI 13.9-15.6), and among aged 18 + years (23.2%, 95% CI 22.4-24.0) compared to aged 5-17 years (18.4%, 95% CI 17.0-19.9). No differences were observed by gender. Individuals exposed to a COVID confirmed case or residing in a COVID containment zone had higher seroprevalence (34.5% and 26.0%, respectively). There was also a wide variation (10.7-33.0%) in seropositivity across 11 districts indicating that population exposed to COVID was not uniform at the time of the study. Since about 78% of the population (36.5 million) in these districts were still susceptible to infection, public health measures remain essential to reduce further spread.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Observational study Limits: Adolescent / Child / Child, preschool / Humans Country/Region as subject: Asia Language: English Journal: J Epidemiol Glob Health Year: 2021 Document Type: Article Affiliation country: S44197-021-00012-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Observational study Limits: Adolescent / Child / Child, preschool / Humans Country/Region as subject: Asia Language: English Journal: J Epidemiol Glob Health Year: 2021 Document Type: Article Affiliation country: S44197-021-00012-6